The contracts call for CSL Behring to supply Helixate FS, Humate, Privigen, Vivaglobin and other life-saving therapies over a period of at least five years, and to provide toll manufacturing services to Canadian Blood Services for the fractionation of Canadian plasma. In addition, with this agreement, CSL Behring will become the main supplier of bleeding disorder treatments in the province of Quebec.
These products are used for the treatment of conditions such as hemophilia, von Willebrand Disease, primary immunodeficiency as well as other serious conditions.
Heinz Neuhaus, general manager of CSL Behring Canada, said: “We at CSL Behring in Canada are quite pleased with the awards. Our company has made significant investments in becoming a reliable partner for both Canadian Blood Services and Hema-Quebec so that we can expand our product offering to Canadian patients in need.”